1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

Henlius’ HLX43 is the second most advanced in the class of PD-L1-targeting ADCs globally, after Pfizer's PDL1V. (Shutterstock)

Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).

Key Takeaways
  • Since January, Chinese firm Henlius has planned or initiated six Phase II studies with HLX43, its PD-L1-targeting ADC, as monotherapy in non-small cell lung and cervical cancer, and nasopharyngeal, esophageal squamous cell, hepatocellular and head and neck squamous cell carcinoma.

On the surface of the hot race, Henlius’s HLX43, the second most advanced globally in the class, appears to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Alkermes Two-For-Two In Narcolepsy As Alixorexton Succeeds In NT2 Trial

 
• By Alaric DeArment

The drugmaker plans to move into Phase III development of the drug, which has now posted positive Phase II results in narcolepsy types 1 and 2.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

enGene’s Detalimogene On Track For H2 2026 FDA Filing In NMIBC

 
• By Alaric DeArment

The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

More from Focus On Asia

Novo-Emcure Semaglutide Deal Clever Counter To Indian Rivals, Follows Lilly-Cipla Pact

 
• By Vibha Ravi

Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call